Multiple Myeloma Clinical Trial
— BVDOfficial title:
A Phase II Study of Bendamustine, Velcade and Dexamethasone (BVD) in the Treatment of Elderly Patients (>= 65 Years) With Multiple Myeloma in 1st Relapse or Refractory to 1st Line Therapy
Verified date | March 2012 |
Source | Intergroupe Francophone du Myelome |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The present trial is designed as a phase II study that aims at estimating the efficacy of the combination of bendamustine, bortezomib and dexamethasone in relapsed/refractory multiple myeloma (MM). The response rate, i.e. the rate of the patients achieving a Complete Response or Partial Response at cycle 4, divided by the total intent to treat patient number is chosen as primary efficacy endpoint. The estimation of the efficacy rate is to be based on an explorative pilot study, since immediate embarking on a large-scale comparative efficacy trial would not be acceptable from the point of view of resources. Moreover, this would induce ethical objections, as it does not seem to be justifiable to expose a large number of patients to an experimental approach without sufficient exploratory indications of an improved risk-benefit ratio.
Status | Completed |
Enrollment | 75 |
Est. completion date | March 28, 2013 |
Est. primary completion date | March 28, 2013 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 65 Years and older |
Eligibility | Inclusion Criteria: - Symptomatic multiple myeloma (MM) patient at the time of diagnosis (but not necessarily at the time of relapse), according to International Myeloma Working Group criteria. - Patient having received conventional chemotherapy in 1st line treatment because of age 65 years or over, or younger than 65 years and ineligible to high-dose therapy plus stem cell transplantation. - Measurable disease (=10g/L monoclonal gammapathy and/or = 200 mg/24h proteinuria or involved serum free light chain = 100mg/L with abnormal FLC ratio < 0.26 or > 1.65) - Patient in 1st relapse or refractory to 1st line therapy. Relapse is defined by M-component increase of =25% from baseline, in serum and/or urine (the absolute increase in serum must be = 5 g/l - the absolute increase of BJ proteins in urine must be =200 mg/24 h). (It is recommended to treat only symptomatic or rapidly evolutive relapses) - Life expectancy of at least 3 months - ECOG performance status <= 2 at study entry - Laboratory test results within these ranges: - Absolute neutrophil count >= 1.5 x 109/L - Platelet count >= 100 x 109/L - Serum creatinine <= 250 umol/l - AST (SGOT) and ALT (SGPT) <= 3 x ULN - Disease free of prior malignancies for >= 5 years, with exception of curatively treated basal cell, squamous cell carcinoma of the skin, or carcinoma "in situ" of the cervix or breast - Able to adhere to the study visit schedule and other protocol requirements - Using effective contraceptive methods during and for 6 months after study treatment (for fertile men, women of childbearing potential). - Provision of informed consent. - A period of at least 15 days must be respected between the last treatment of myeloma and the beginning of the study. Exclusion Criteria: - Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form. - Any comorbidity which places the subject at unacceptable risk if he/she were to participate in the study. - Patients treated with high-dose therapy plus stem cell transplantation in 1st line therapy - Any prior use of bortezomib (Velcade) or bendamustine (Ribomustin) - Concurrent use of other anti-cancer agents or treatments other than those stated in this treatment plan - Use of any other experimental drug or therapy within 28 days prior to the start of study treatment. - Known hypersensitivity to the study drugs - Positive HIV serology, positive hepatitis C serology, active infection hepatitis A, active infection hepatitis B. - Severe cardiovascular disorders within 12 months prior to the start of study treatment (e.g. myocardial infarct, ischemic episodes, arrhythmias) - Previous major surgery less than 30 days before start of treatment - Active infection, - Pregnant or lactating women. |
Country | Name | City | State |
---|---|---|---|
France | CHRU Hôpital Sud | Amiens | |
France | CHRU, Hôpital du Bocage | Angers | |
France | Centre Hospitalier H.Duffaut | Avignon | |
France | Centre Hospitalier de la Cote Basque | Bayonne | |
France | Hôpital Jean Minjoz / CHU BESANCON | Besançon | |
France | Centre Hospitalier | Blois | |
France | Hôpital Avicenne | Bobigny | |
France | Polyclinique Bordeaux Nord Aquitaine | Bordeaux | |
France | Hôpital A.Morvan | Brest | |
France | Centre F.Baclesse | Caen | |
France | CHU Clermont Ferrand | Clermont Ferrand | |
France | CH Sud Francilien | Corbeil-essonnes | |
France | CHU DIJON, Hôpital Le Bocage | Dijon | |
France | Centre Hospitalier Général | Dunkerque | |
France | Hôpital A.Michallon | Grenoble | |
France | CH Départemental | La Roche Sur Yon | |
France | Centre Hospitalier de Chartres | Le Coudray | |
France | Centre Jean Bernard | Le Mans | |
France | CHRU Hôpital Claude Huriez | Lille | |
France | Institut Paoli Calmette | Marseille | |
France | CH MEAUX | Meaux | |
France | CHRU Hôtel Dieu | Nantes | |
France | Hôpital de l'Archet 1 | Nice | |
France | CHU Hôpital St-Antoine | Paris | |
France | Intitut Curie | Paris | |
France | Centre Hopsitalier Lyon Sud | Pierre Benite | |
France | Centre Hospitalier René Dubos | Pontoise | |
France | Centre Hospitalier de la Région d'Annecy | Pringy | |
France | CHU Reims Hôpital R.Debré | Reims | |
France | CHRU - Hôpital sud | Rennes | |
France | Centre Henri Becquerel | Rouen | |
France | Centre René Huguenin | Saint-cloud | |
France | CHRU Hopital Purpan | Toulouse | |
France | CHRU Hopital Bretonneau | Tours | |
France | Centre Hospitalier | Valence | |
France | CHRU - Hôpitaux de Brabois | VandÅ“uvre-lès-Nancy | |
France | CH P.Chubert | Vannes |
Lead Sponsor | Collaborator |
---|---|
Intergroupe Francophone du Myelome |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To assess of the overall response rate (complete response (CR) + partial response (PR)) | After four 28-day consecutives cycles | ||
Secondary | Time to best response | the time from treatment start to the first detection of the best response category, calculated for all patients, which are not primarily refractory | ||
Secondary | Progression-free survival | The time form the initial dose of chemotherapy to the time of disease progression or death, or to the date of last assessment without any such event (censored observation) | ||
Secondary | Time to progression | The time from baseline to the development of progressive disease | ||
Secondary | Overall survival | The time interval from initial dose to the date of death or last observation (censored) | ||
Secondary | Rate of additional response | Following 2 consolidation cycles and following 6 maintenance cycles | ||
Secondary | Toxicity/Adverse events | From the time a signed and dated informed consent form is obtained until 60 days following the lase dose of study medication or until the start of a new subsequent antimyeloma therapy |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05027594 -
Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT02412878 -
Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma
|
Phase 3 | |
Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05971056 -
Providing Cancer Care Closer to Home for Patients With Multiple Myeloma
|
N/A | |
Recruiting |
NCT05243797 -
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
|
Phase 3 | |
Active, not recruiting |
NCT04555551 -
MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma
|
Phase 1 | |
Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Completed |
NCT02916979 -
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
|
Phase 1 | |
Recruiting |
NCT03570983 -
A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion
|
Phase 2 | |
Completed |
NCT03665155 -
First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody
|
Phase 1/Phase 2 | |
Terminated |
NCT03399448 -
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
|
Phase 1 | |
Completed |
NCT02812706 -
Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05024045 -
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
|
Phase 1 | |
Active, not recruiting |
NCT03792763 -
Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients
|
Phase 2 | |
Active, not recruiting |
NCT03989414 -
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
|
Phase 1/Phase 2 | |
Withdrawn |
NCT03608501 -
A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation
|
Phase 2 | |
Recruiting |
NCT04537442 -
Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT02546167 -
CART-BCMA Cells for Multiple Myeloma
|
Phase 1 |